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AIDS has changed from a mostly male-speciﬁc health problem to one that predominantly affects females. Although sex differences in
HIV-1 susceptibility are beyond doubt, the extent to which sex affects the onset and progression of AIDS has remained elusive. Here, we
provide evidence for an inﬂuence of X chromosomal variation on the course of retroviral infection, both in HIV-1-infected patients and
in the rhesusmacaquemodel of AIDS. A two-stage, microsatellite-basedGWAS of SIV-infectedmonkeys revealedMHC class I markers and
a hitherto-unknown X chromosomal locus as being associated with a nominal score measuring progression to AIDS (Fisher’s exact
p < 106). The X chromosomal association was subsequently conﬁrmed in HIV-1-infected patients with published SNP genotype
data. SNP rs5968255, located at human Xq21.1 in a conserved sequence element near the RPS6KA6 and CYLC1 genes, was identiﬁed
as a signiﬁcant genetic determinant of disease progression in females (ANOVA p¼ 8.83 105), but not inmales (p¼ 0.19). Heterozygous
female carriers of the C allele showed signiﬁcantly slower CD4 cell decline and a lower viral load at set point than TT homozygous
females and than males. Inspection of HapMap revealed that the CT genotype is signiﬁcantly more frequent among Asians than among
Europeans or Africans. Our results suggest that, in addition to the individual innate and adaptive immunity status, sex-linked genetic
variation impacts upon the rate of progression to AIDS. Elucidating the mechanisms underlying this sex-speciﬁc effect will promote
the development of antiretroviral therapies with high efﬁcacy in both sexes.Introduction
Susceptibility to an infection with human immunodeﬁ-
ciency virus type 1 (HIV-1 [MIM 609423]) and the progres-
sion to the acquired immunodeﬁciency syndrome (AIDS
[MIM 609423]) are inﬂuenced by (1) the pathogenicity of
the virus, (2) the functionality of various innate and adap-
tive immune defense proteins, and (3) additional host
factors with a bearing upon, for example, viral entry and
replication.1 Consequently, the ﬁrst genome-wide associa-
tion study (GWAS) of HIV-1-infected patients unraveled
single-nucleotide polymorphisms (SNPs) in the major
histocompatibility complex class I region (MHC [MIM
142800]) asmajor determinants of both the individual viral
load (VL) at set point and the rate of disease progression.2
Subsequent GWAS conﬁrmed the prominent role of the
MHC region in modulating the clinical course of HIV-1
infection.3–5 In addition, however, functional genomic
studies identiﬁed hundreds of other genes that may inﬂu-
ence theHIV-1 life cycle.6–8 This implies that a largenumber
of host factors are likely to contribute to the variability of
the HIV-related phenotypes, including genetic variants
the nature and frequency of which supposedly depend
upon the ethnic background of the respective patients.
One way to promote the discovery of genetic and nonge-
netic determinants of human disease phenotypes is their228 The American Journal of Human Genetics 85, 228–239, Auguststudy in relevant animal models. Despite a couple of
pathophysiological differences that exist between HIV-1
and simian immunodeﬁciency virus (SIV) infection, SIV-
infected rhesus macaques still represent the most impor-
tant animal model for preclinical proof-of-concept studies
of HIV vaccines and microbicides and for pathogenicity
studies.9–11 Therefore, rhesus macaques may potentially
also provide an excellent means to identify genetic vari-
ants that are involved in a differential response to retro-
viral infections.
Because genome-wide SNP arrays and HapMap-like
resources are not yet available for nonhuman primates,
we chose to perform a step-wise microsatellite-based
GWAS in two independent samples of SIV-infected rhesus
macaques of Indian descent (Macaca mulatta), both of
which displayed interindividual differences in terms of
their progression to AIDS. Our study not only conﬁrmed
the disease relevance of genetic variation in the MHC but
also identiﬁed an X chromosomal locus as being associated
with the rate at which SIV infection leads to the onset of
AIDS-related disease in rhesus macaques. We then success-
fully translated this ﬁnding into the human system by
identifying an X chromosomal SNP, rs5968255, as being
signiﬁcantly associated with both individual VL at set
point and the rate of disease progression in HIV-1-infected
women, deﬁned either by the time until treatment1Genome Analysis, Leibniz Institute for Age Research—Fritz Lipmann Institute, Beutenbergstr. 11, 07745 Jena, Germany; 2German Primate Center, Leibniz
Institute for Primate Research, Kellnerweg 4, 37077 Go¨ttingen, Germany; 3Cologne Center for Genomics, University of Cologne, Zu¨lpicher Straße 47,
50674 Cologne, Germany; 4Institute of Medical Informatics and Statistics, Christian-Albrechts-University, Brunswiker Str. 10, 24105 Kiel, Germany;
5Center for Human Genome Variation, Duke Institute for Genome Sciences & Policy, Duke University, Durham, NC 27710, USA; 6Center for Molecular
Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931 Cologne, Germany; 7Cologne Excellence Cluster on Cellular Stress Responses in
Aging-Associated Diseases (CECAD), University of Cologne, Zu¨lpicher Straße 47, 50674 Cologne, Germany
8These authors contributed equally to this work
*Correspondence: rsidd@ﬂi-leibniz.de
DOI 10.1016/j.ajhg.2009.07.013. ª2009 by The American Society of Human Genetics. All rights reserved.14, 2009
Table 1. Screening and Verification Samples of SIV-Infected Rhesus
Sex Stage 1 (n ¼ 136) Stage 2 (n ¼ 128) p Valuea
101 males (74%) 110 males (86%) 0.021
35 females (26%) 18 females (14%)
Average Progression Score (5 Standard Deviation)
all 3.15 5 1.23 3.18 5 1.07 0.152
males 3.16 5 1.22 3.19 5 1.05 0.064
females 3.11 5 1.26 3.11 5 1.23 0.323
Average Survival Time (Weeks after Infection 5 Standard Error)
all 67.30 5 5.09 83.25 5 11.15 0.899
males 70.46 5 6.49 88.23 5 12.90 0.841
females 59.55 5 7.15 53.90 5 6.71 0.347
a All p values relate to the differences between stage 1 and stage 2 samples. They refer to Fisher’s exact test, except for survival time for which the p value refers to
a log-rank test.initiation or the time until CD4 cells have dropped below
350 ml1.
Material and Methods
Monkey Samples
For the present study, retrospective data were compiled from
different SIV infection studies on rhesus macaques of Indian
descent, performed at the German Primate Center (‘‘Deutsches
Primatenzentrum,’’ DPZ, see Table 1 and Tables S1–S3 available
online). The housing and treatment protocols of the DPZ follow
the German Animal Protection Act, which in turn complies with
European Union guidelines on the use of non-human primates
for biomedical research and have been approved by the respon-
sible public authority. All animals were housed, surveyed, and
SIV-infected with standardized or highly similar protocols. The
time point and route of SIV infection, the date of death, previous
treatments, the dose of infecting virus, and the identity of the
infecting virus strain itself were known for all monkeys. Necropsy
results, hemograms and antibody titers were also generally avail-
able. Cell-associated viral-load data and viral RNA copy number
were known for the majority of animals. Most monkeys had been
infected with SIVmac251 or SIVmac239 (Tables S1–S3). Given that
both strains are of similar pathogenicity,12,13 confounding of our
GWAS by strain identity appears to be unlikely. Furthermore, no
signiﬁcant association was observed between the infecting strain
and the progression score that constituted the core phenotypic
measure of our study (see below), neither in stage 1 (Fisher’s exact
p ¼ 0.139) nor in stage 2 (p ¼ 0.325) of the GWAS.
Deﬁnition of Progression Score
Some 46% of the monkeys in GWAS stage 1, and 32% of animals
in stage 2, were euthanized before they had developed AIDS-
related symptoms or were still alive by the end of the study. In
addition, ~40% of the monkeys were immunized with a prospec-
tive AIDS vaccine before infection. None of the vaccines tested
reduced VL at set point substantially but may have prolonged
survival. This implies that time of survival after SIV infection alone
would have been an insufﬁcient basis for the envisaged GWAS of
disease progression. To overcome this caveat, we scored diseaseThe Amerprogression on a scale of 1 to 5 points, with adjustments made
for immunization effects (Figure 1). Individual scores were based
upon survival time, necropsy results, antibody titer, available
viral-load data, CD4þ T cell counts, and neopterin values. This
scoring system reﬂects our long-term experience in evaluating
genetic, immunological, and virological data on the course of
SIV infection in rhesus macaques. The scoring system not only
divides the bulk of monkeys into fast (score 2), medium (score 3),
and slow progressors (score 4) but also allows a more nuanced
consideration of the extreme ends of the disease spectrum (ultra-
fast progression: score 1, long-term nonprogression: score 5).
The diagnosis of AIDS-related disease was based upon clinical,
necropsy, and histopathology ﬁndings. For monkeys to be
diagnosed with AIDS-related disease, they had to suffer from
anorexia, incurable diarrhea, or neurological or lung dysfunction,
evidenced by ataxia or respiratory sounds. Necropsy and
histology ﬁndings had to reveal one or more of the following:
severe hyperplasia of secondary lymphoid tissue, severe chronic
active gastroenteritis, chronic interstitial pneumonia associated
with Pneumocystis jirovecii infection, giant cell disease, or enceph-
alopathy. Lymphomas, nonbacterial thrombotic endocarditis, or
artheriopathy were regarded as additional AIDS-related complica-
tions and were used for conﬁrmation of the primary diagnosis.
Notably, CD4þ T cell count was not found to be an adequate diag-
nostic marker of AIDS because many rapid progressors still had
physiological CD4þ T cell counts by the time of euthanasia.14,15
For monkeys euthanized without a diagnosis of AIDS-related
disease, necropsy and histopathology ﬁndings were used in deter-
mining whether they were at a pre-AIDS stage. The minimum
prerequisite for this diagnosis was the presence of moderate to
severe hyperplasia of lymphoid tissue in combination with
moderate to severe chronic gastroenteritis. Animals presenting
with either AIDS-related disease or at a pre-AIDS stage were scored
according to their survival time after infection, taking into
account whether or not they had been immunized prior to infec-
tion (Figure 1).
Monkeys that were still alive at the end of the study (all at >
100 weeks post infectio [wpi]), or that were euthanized without
a diagnosis of AIDS-related disease or pre-AIDS, were scored either
4 or 5, depending upon their CD4þ T cell count and viral load
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the absence of any signs of immunodeﬁciency (i.e., a stable CD4þ
T cell count), together with a cell-associated viral load< 3 infected
cells per 107 cells or a plasma viral load< 1000 RNA copiesmL1 at
set point. Long-term nonprogressors usually survive SIV infection
substantially longer (>300 wpi) than slow progressors (score 4).
Indeed, among the SIV-infected animals kept at the DPZ, this
leap in survival time coincides perfectly with the differences in
viral load and CD4þ T cell count deﬁning the progression score,
even at an early stage after infection.
Microsatellite Genotyping
In the screening stage (stage 1) of our microsatellite-based GWAS,
136 SIV-infected rhesus macaques were genotyped for a genome-
wide set of 332 microsatellites. Human as well as Macaca mulatta-
speciﬁc microsatellites that had been selected on the basis of
published mapping information were used.16 All microsatellites,
their chromosomal location, and the forward and reverse primers
used for ampliﬁcation are listed in Tables S4 and S5. For each of
the 14 non-MHCmarkers selected for veriﬁcation in 128 additional
SIV-infected animals (stage 2 of our GWAS), we included two
additional ﬂanking markers located ~250 kb up- and downstream
of the original marker, respectively. These markers were identiﬁed
through a systematic search for microsatellite sequences of the
published Macacca mulatta genomic sequence (build 1.1). Assays
were designed with the PRIMER 3 software (see Web Resources).
Fragment sizes were measured by separation of PCR products
on an ABI 3700 capillary sequencer (Applied Biosystems) and by
subsequent data analysis with the Genemarker software (Softge-
netics LLC).
Microsatellite-Based Association Analysis
in Rhesus Macaques
Hemizygosity for X chromosomalmicrosatellites was veriﬁed in all
male monkeys, and apparently heterozygous genotypes were
excluded from subsequent analyses. The level of allelic association
between individualmarkers and the progression score was assessed
for statistical signiﬁcance with Fisher’s exact test. p values were
calculated by Monte-Carlo Markov-Chain simulation. Bonferroni
Figure 1. Decision-Tree-BasedDefinition
of a Progression Score for SIV-Infected
Rhesus Macaques
The diagnosis of AIDS-related disease was
based upon clinical, necropsy, or histopa-
thology ﬁndings. Animals that were eutha-
nized with AIDS-related disease or as being
at a pre-AIDS stage were scored according
to their survival time after SIV infection.
Monkeysnot at apre-AIDSstageafter eutha-
nasia, or not euthanized at all, were scored
according to theirCD4cell decline andviral
load (plasma viral load < 1000 RNA copies
mL1 or cell-associated viral load < 3
infected cells per 107 cells at set point).
correction for multiple testing was carried
out in stage 1 of the GWAS (Table S4 and
Figure S6), although the actual selection
of markers for veriﬁcation in stage 2 (5%
of the total markers) was based solely
upon relative signiﬁcance and resource
availability rather than genome-wide
statistical signiﬁcance. In stage 2, each original marker and its
two ﬂanking neighbors were treated as one marker group (Table
S5). p values were ﬁrst corrected according to Holm17 within each
marker group, and the most signiﬁcant marker and its corrected
p value were selected to represent the respective group. In a second
step, the corrected p values of the group representative and the
p values of three additional MHC markers were further corrected
for multiple testing according to Holm.
Assessment of Population Stratiﬁcation in theMonkey
Veriﬁcation Sample
To quantify the level of population stratiﬁcation in the veriﬁcation
sample (stage 2), members of which originally came from four
different centers, we calculated FST according to the deﬁnition of
Weir and Cockerham18 by using an implementation in FSTAT
(version 2.9.3; see Web Resources).
Data and Quality Control for the SNP-Based
Association Analysis of the CHAVI Sample
We reanalyzed genotype data from a recent GWAS on host control
determinants in HIV-1 infection, undertaken by the Centre for
HIV/AIDS Vaccine Immunology (CHAVI).2 VL at set-point data
and a progression phenotype, deﬁned by the CHAVI investigators
as the time until either treatment initiation or a drop in CD4
cell count below 350 cells mL1, were available for 303 (93 females,
210 males) of the 486 original samples. For these individuals,
we were provided the genotypes of all 13,821 X chromosomal
SNPs generated in the CHAVI study.2 Correct sex assignment
was veriﬁed with the proportion of heterozygous genotypes
at all markers (average percentage expected in males: <1%, in
females: ~25%). Average pair-wise identity by state (IBS) was used
for the assessment of extreme genetic similarity and dissimilarity,
pointing at cognate relatives or genetic outliers, respectively. For
post hoc quality control after association analysis (see below),
we required nominally signiﬁcant SNPs to have a call-rate R
95% and to be in Hardy-Weinberg equilibrium (p > 0.05, with
an exact test).19 Quality control was carried out with the R soft-
ware version 2.6.2.20230 The American Journal of Human Genetics 85, 228–239, August 14, 2009
Assessment of Population Stratiﬁcation in the CHAVI
Sample
To account for possible population stratiﬁcation in the statistical
analyses of the human genotypes, we used a principal component
(PC)-based approach as implemented in EIGENSTRAT.21 Given
that EIGENSTRAT can only handle autosomal genotypes, we
assumed each male to be homozygous for each X chromosomal
marker and females were doubled to ensure unchanged allele
frequencies. A recent survey of genome-wide autosomal genetic
variation in Europe revealed considerable variation only in the
ﬁrst ﬁve to six PCs.22 Therefore, we considered the ﬁrst six PCs
of the X chromosomal markers as sufﬁcient to adjust our analyses
of the CHAVI sample for potential population stratiﬁcation as
well.
Association Analysis in the CHAVI Sample
We normalized progression phenotype values by taking natural
logarithms. Possible deviations from normality were tested for
statistical signiﬁcance with a Shapiro-Wilk test. To assess possible
population stratiﬁcation in the CHAVI sample, we subjected the
ﬁrst six PCs from the EIGENSTRAT analysis of the X chromosomal
genotype data to a multiple linear regression analysis of the log-
progression phenotype. AIC-based backward selection retained
only the second and the sixth PC in the model. We then used
ANOVA, stratiﬁed by sex and including the two signiﬁcant PCs
as covariates, to test for statistically signiﬁcant associations
between individual X chromosomal SNP genotypes and the log-
progression phenotype and associations with VL at set point. All
analyses were carried out with R version 2.6.2.20 The association
between SNP rs5968255 and VL at set point was tested for statis-
tical signiﬁcance with linear regression modeling,2 including age
at seroconversion and the two signiﬁcant EIGENSTRAT PCs as
covariates.
Linkage Disequilibrium Analysis
We used HaploView 4.1 separately for males and females to esti-
mate linkage disequilibrium (LD) and to deﬁne tag SNPs.23,24 We
used the CEU (Utah residents with ancestry from northern and
western Europe) genotype data of the HapMap project, release
23a (phase II, March 2008) to infer which SNPs were in LD with
each other at a population level.25
Kaplan-Meier Survival Analysis
In the monkey samples, we performed Kaplan-Meier survival anal-
ysis with log-rank statistics to assess the observed genotype-
speciﬁc differences in survival after SIV infection for their
statistical signiﬁcance. In the CHAVI samples, Kaplan-Meier
analyses of the progression phenotype were performed in addi-
tion to ANOVA to allow a more detailed illustration of the geno-
typic effects upon progression phenotype. Kaplan-Meier plots
were created with R version 2.6.2 and with Sigmaplot 11 (Systat
Software).
Synteny Analysis
Synteny between X chromosomal regions in humans and
macaques was veriﬁed with the tuple plot program for pair-wise
nucleotide sequence comparison with noise suppression.26 The
human Xq21.1 region, spanning coordinates 71,657,686 to
86,891,379 inNCBI Build 36.1,was compared to the rhesusX chro-
mosomal regionspanningcoordinates 71,459,512 to86,479,549of
Mmul_051212.The AmerResults
Genetic Variations in the MHC Class I Region and
on Chromosome X Are Associated with Disease
Progression in the Rhesus Macaque Model of AIDS
We performed a microsatellite-based GWAS of host factors
that inﬂuence AIDS-free survival in SIV-infected rhesus
macaques of Indian origin. The markers were derived
mainly from the published linkage map of the rhesus
macaque.16 An initial, pedigree-based linkage analysis of
the available animals was dismissed after the number of
genetically veriﬁable relationships turned out to be too
small to achieve sufﬁcient credibility (data not shown).
We therefore reverted to a two-stage association analysis,
by using 136 SIV-infected monkeys for screening in stage
1 (Table 1; Tables S1 and S2). Prominent association signals
obtained in stage 1 were selected for veriﬁcation in stage 2,
in which an independent group of 128 unrelated SIV-
infected animals was analyzed (Table 1; Table S3). In order
to ensure consistent phenotyping, we used a scoring
system for the progression rate toward AIDS-related disease
(Material and Methods; Figure 1). The samples used in
stages 1 and 2 were characterized by similar average
progression scores and similar average AIDS-free survival
times (Table 1).
A total of 332 microsatellite markers were genotyped in
stage 1 (call-rate > 90%). The average intermarker genetic
distance was ~9 centiMorgans (cM). With a Monte-Carlo
Markov-Chain implementation of Fisher’s exact test, 83
markers were found to exhibit a nominally signiﬁcant
allelic association with the progression score (p % 0.05).
Four of these associations remained signiﬁcant after Bon-
ferroni correction (Table 2; Table S4), namely D6S2972
(p% 106), D6S2704 (p ¼ 1.2 3 104), D2S434 (p ¼ 2.4 3
105), and MML9S30 (p % 106). Markers D2S434 and
MML9S30 are located on rhesus chromosomes 12 and 9,
respectively; D6S2972 and D6S2704 are located in the rhe-
sus MHC class I region on chromosome 4 (Table 2).
For veriﬁcation of the results of stage 1, the top 5% of
markers with the smallest p values (n¼ 17) were genotyped
in a second sample of animals. This set of markers included
3MHCmarkers, 13markers from other autosomal loci, and
1 X chromosomal marker. For each of the non-MHC
markers, two additional ﬂanking polymorphisms ~250 kb
apart from the original marker were included in the geno-
typing. In total, 45 microsatellites were genotyped in
stage 2 (Table S5). Of these, only X chromosomal microsa-
tellite DXS986 (p ¼ 3.2 3 103) and its two neighbors
(DXS986þ1, p % 106; DXS9862, p ¼ 6.2 3 105)
exhibited a statistically signiﬁcant association with the
progression score after multiple testing correction (Table
2). The two MHC markers D6S2704 and D6S2972 retained
nominal signiﬁcance, whereas the phenotype association
ofD2S434 andMML9S30 could not be conﬁrmed in stage 2
(Table 2; Tables S4 andS5). Theveriﬁcationof theMHC asso-
ciation was not surprising because MHC class I genes are
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both rhesus macaques and humans.1,13,27,28 Although
some marginal population substructure became apparent
in the veriﬁcation sample (FST ¼ 0.035), this was deemed
too small to have inﬂated the signiﬁcance of our results.
Subgroup analyses of naive and immunized animals
revealed that the association between DXS986 and the
progression score achieved nominal signiﬁcance in both
subsets of stage1 (p¼1.13104 innaive animals, p¼0.027
in immunized animals). In stage 2, the two subgroup-
speciﬁc p values were of borderline signiﬁcance (0.05 <
p < 0.10). These results argue against any notable con-
founding of the association between DXS986 and the
progression score by the immunization state. A sex-speciﬁc
subgroup analysis was not deemedmeaningful because the
number of femaleswas too low in the two stages (35 and 18,
respectively) to provide sufﬁcient statistical power.
Analysis of X Chromosomal SNPs in HIV-1-Infected
Patients
In order to investigate whether our results in macaques
would also apply to HIV-infected humans, we obtained
phenotypic and X chromosomal SNP genotype data from
a recent human GWAS, carried out by the Centre for
Table 2. Detection and Verification of the Top 5% Associations
with Progression Score, as Obtained in Stage 1 of a Microsatellite-
Based GWAS in SIV-Infected Rhesus Macaques
Marker Chromosome
Location
(Mmul_051212)
Stage 1
p Valuea
Stage 2
p Valueb
D6S2972 4 29414233 <106 5.0 3 103
MML9S30 9 127592629 <106 0.416
D2S434 12 81515926 2.4 3 105 0.718
D6S2704 4 29800682 1.2 3 104 2.9 3 103
D8S322 8 22034079 8.6 3 104 0.863
D7S496 3 144937483 1.2 3 103 0.137
DXS986 X 78914283 1.2 3 103 <106
D3S1583 2 167994335 1.5 3 103 0.447
D5S2122 6 68784187 1.6 3 103 0.021
D7S524 3 132219500 1.9 3 103 0.607
D1S215 1 191075285 2.0 3 103 0.064
D2S2364 13 78819370 2.0 3 103 0.579
MML6S8 6 91055880 2.0 3 103 0.556
MML10S14 10 52709132 2.4 3 103 0.463
D7S493 3 104444180 3.1 3 103 0.620
D6S2876 4 32439777 3.7 3 103 0.269
MML9S32 9 129952729 3.7 3 103 0.168
a Fisher’s exact test;
b Except for the three MHC markers (D6S*), p values represent the minimum
of a set of three Holm-corrected p values, including the original marker plus
two flanking markers located ~250 kb upstream and downstream, respectively.
For D6S2972, D6S2704, and D6S2876, p values are uncorrected and corre-
spond to a single marker only. The X chromosomal marker (DXS986) that
yielded a significant result in both GWAS stages is highlighted in bold.232 The American Journal of Human Genetics 85, 228–239, August 1HIV/AIDS Vaccine Immunology (CHAVI).2 In the CHAVI
study, the progression phenotype was deﬁned as either
the time until treatment initiation or the time until the
CD4 cell count was observed or extrapolated to have drop-
ped below 350 cells mL1, a threshold recommended by
many guidelines for the initiation of antiretroviral treat-
ment. In the natural course of HIV-1 infection, this event
often signiﬁes the transition from a nonsymptomatic
state to the phase of AIDS-deﬁning illnesses and death, if
not treated.29 We studied 303 seroconverters (93 females,
210 males) for whom the progression phenotype and
information on the VL at set point were available.
After synteny between the region surrounding DXS986
in macaques and Xq21.1 in humans had been conﬁrmed
(Figure S1), we performed an association analysis (Table 3;
Table S6) by using 128 SNPs from a 15 Mb region centered
at DXS986 (NCBI Build 36.1 coordinates 71,657,686 to
86,891,379). The region of interest was ﬂanked at its prox-
imal end byMMLXS5, the nearest nonsigniﬁcant marker in
stage 1 of the rhesus GWAS (Table S4). After Bonferroni
correction, sex-stratiﬁed ANOVA without adjustment for
population structure revealed ﬁve SNPs from the DXS986
region to be signiﬁcantly associated with the log-progres-
sion phenotype in females (data not shown). When the
two signiﬁcant PCs were included as covariates, only the
association with rs5968255 remained signiﬁcant. Notably,
no signiﬁcant association with the log-progression pheno-
type was observed for males. Multiple linear regression
analysis of the log-progression phenotype and the ﬁve
signiﬁcant SNPs around DXS986, involving AIC-based
backward selection with and without inclusion of the
two signiﬁcant PCs, conﬁrmed rs5968255 as the only
signiﬁcantly associated marker in the DXS986 region after
Bonferroni correction (corrected p ¼ 1.3 3 102; nominal
p ¼ 8.8 3 105 in females, nominal p ¼ 0.19 in males;
Table S7).
Some of the SNPs analyzed in the CHAVI sample showed
considerable allelic association with one another, thereby
rendering Bonferroni correction for multiple testing overly
conservative. We therefore repeated the initial association
analysis of the CHAVI data with the assumption that the
number of tag SNPs24 in the region or interest represented
a good approximation of the number of independent
hypotheses tested. Pair-wise r2 SNP tagging was carried
out with HaploView 4.1.23 Employing either 0.8 or 0.5
as tagging thresholds yielded 109 and 92 tag SNPs (out
of 128 SNPs) in the DXS986 region, respectively. However,
even when these ﬁgures were used for relaxed multiple-
testing correction, the number of signiﬁcant results re-
mained virtually unchanged (data not shown).
SNP rs5968255 Is Associated with Slower Progression
in Women Only
The allele and genotype frequencies of rs5968255 in the
CHAVI sample, which consists of individuals of self-
reported European ancestry,2 were found to be similar to
those in the European American HapMap sample (CEU).4, 2009
In both instances, T was the major allele (CEU frequency:
0.88) and C was the minor allele (CEU frequency: 0.12).25
Data from chimpanzee suggest that T represents the ances-
tral state of this SNP. When the CHAVI samples were strati-
ﬁed by sex, 20 out of 210 males (9.5%) were found to be
hemizygous for the C allele. Of the 93 females, 77 (82.8%)
were homozygous TT and the remaining 16 women
Table 3. Ten Most Significant Associations between X
Chromosomal SNPs and the Progression Phenotype in the CHAVI
Sample, with and without Stratification by Sex
SNP Coordinate p Valuea
Males
rs959060 86553764 3.1 3 103
rs5924105 86889097 8.3 3 103
rs2092545 83518130 0.016
rs1573906 86022244 0.018
rs5938679 75919876 0.022
rs2214607 75322143 0.028
rs5969113 86313544 0.034
rs4892718 76098975 0.044
rs1905182 82482574 0.051
rs5923642 85930864 0.052
Females
rs5968255 83141348 8.8 3 105
rs10218349 83276159 7.4 3 104
rs2092545 83518130 8.4 3 104
rs825541 82936504 8.5 3 104
rs1531868 82991939 8.5 3 104
rs10855652 86303530 1.7 3 103
rs1515024 78701951 1.8 3 103
rs527480 73552592 3.2 3 103
rs7879492 84905281 5.5 3 103
rs765076 83390987 7.5 3 103
Combined
rs5922075 83811026 1.1 3 103
rs959060 86553764 1.3 3 103
rs5968255 83141348 1.8 3 103
rs7879492 84905281 3.3 3 103
rs6623084 83850582 3.6 3 103
rs10218349 83276159 5.6 3 103
rs7882767 84775710 6.1 3 103
rs6617219 85444095 9.0 3 103
rs7879396 79513028 9.9 3 103
rs5923642 85930864 0.011
a Analysis of variance (ANOVA) including the two most significant EIGEN-
STRAT PCs as covariates.The Amer(17.2%)wereheterozygousCT.NohomozygousCCfemales
were observed.
Theprogressionphenotypewas indicative of a signiﬁcant
delay ofCD4 cell loss inCTheterozygous females compared
to TT homozygotes (Kaplan-Meier analysis, log rank p ¼
0.001; Figure 2 and Figure S2). No such effect was seen in
C hemizygous males. Furthermore, heterozygous females
showed a higher median progression phenotype (8.0 years,
IQR: 5.1–20.4 years) than homozygotes (2.2 years, IQR:
1.3–4.4 years). No such trend was apparent among males
(hemizygous T median: 2.6 years, IQR: 1.4–3.9 years;
C median: 1.8 years, IQR: 1.1–2.7 years). In a linear-regres-
sion analysis, SNP rs5968255 explainedbetween21% (coef-
ﬁcient of determination R2; no adjustment for population
stratiﬁcation) and 25% (inclusion of the two signiﬁcant
EIGENSTRATPCs) of the variance in female log-progression
phenotype, indicating a comparatively goodmodel ﬁt. The
association analysis between rs5968255 and the VL at set
point also yielded sex-speciﬁc results (see Table 4, Table S7,
and Figure S3). Here, CT heterozygous females showed
a lower average VL than TT homozygous females (p ¼
0.001), and no signiﬁcant difference was seen between
T and C hemizygous males (p ¼ 0.2). For both ﬁndings, an
artifact due to a hidden association between rs5968255
and the two previously established genetic markers of
both VL and the progression phenotype in the CHAVI
sample,2 namely rs2395029 (a proxy for HCP5 [MIM
604676] and HLA-B*5701 [MIM 142830]) and rs9261174
(ZNRD1 [MIM 607525] and RNF39 [MIM 607524]), could
Figure 2. Kaplan-Meier Analysis of the Progression Phenotype,
Stratified by rs5968255 Genotype and Sex
Among CT heterozygous females, the median progression time
(8.0 years), i.e., the median time until treatment initiation or until
a drop of the individual CD4 cell count below 350 cells mL1 has
occurred, was signiﬁcantly longer (p ¼ 0.001, log rank test) than
among TT homozygotes (2.2 years), or males (T: 2.6 years, C: 1.8
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be systematically excluded (Tables S8 and S9). Therefore,
rs5968255 represents an X-linked genetic variant that
independently impacts upon the progression phenotype
exclusively in HIV-1-infected females.
SNP rs5968255 is located in a 500 bp conserved inter-
genic region (Figure 3), 3.9 Mb distal to DXS986. It resides
64 kb proximal to the ribosomal protein S6 kinase 6 gene
Table 4. Ten Most Significant Associations between X
Chromosomal SNPs and Viral Load at Set Point, with and without
Stratification by Sex
SNP Coordinate p Valuea
Males
rs5981378 74744696 0.013
rs5923575 85772687 0.013
rs12014367 78761577 0.014
rs2092545 83518130 0.019
rs6617219 85444095 0.02
rs2038193 85174711 0.034
rs6647911 75203875 0.035
rs5968183 82634435 0.042
rs527480 73552592 0.043
rs2858719 86046788 0.046
Females
rs10218349 83276159 9.9 3 104
rs5968255 83141348 1.2 3 103
rs5922395 86357637 1.2 3 103
rs2092545 83518130 1.8 3 103
rs6623084 83850582 3.4 3 103
rs825541 82936504 4.3 3 103
rs1531868 82991939 4.3 3 103
rs4828291 83912613 5.3 3 103
rs5922075 83811026 6.2 3 103
rs5969041 86129916 0.044
Combined
rs761202 85819695 2.6 3 103
rs11092732 85073796 5.4 3 103
rs5938152 74799722 7.4 3 103
rs12164321 85766510 9.7 3 103
rs6647780 74740571 0.011
rs1938012 74916674 0.011
rs5922075 83811026 0.013
rs232957 76059032 0.013
rs5969181 86510305 0.018
rs12687256 75219576 0.018
a Analysis of variance (ANOVA) including the two most significant
EIGENSTRAT PCs as covariates.234 The American Journal of Human Genetics 85, 228–239, August(RPS6KA6 alias RSK4 [MIM 300303]) and 138 kb distally
to the cylicin 1 gene (CYLC1 [MIM 300768]). The 30 end
of an alternatively spliced CYLC1 cDNA clone (accession
number BC038787) is located only 233 bp proximally to
rs5968255. Because rs5968255 itself may not be causal
for the observed association, we identiﬁed those SNPs in
the DX6986 region that showed at least moderate LD
(r2 R 0.4) with rs5968255 in the HapMap CEU sample
(Table S10).25 This analysis did not yield any additional
association signals that would have pointed toward
possible candidates for causation. Using the Genevar data-
base,30 we also failed to obtain any evidence for an associ-
ation between rs5968255 and the expression level of either
CYLC1 or RPS6KA6 (data not shown).
HapMap Population Differences in the Allele
Frequencies of SNP rs5968255
The HapMap project has been initiated to catalog common
DNA sequence variation in different human population
groups. The following populations have been included:
YRI, Yoruba from Ibadan, Nigeria; JPT, Japanese from
Tokyo; CHB, Han Chinese from Beijing, China; and CEU,
CEPH (Utah residents with ancestry from northern and
western Europe). Inspection of the respective genotype
data revealed that C represents the minor rs5968255 allele
among females in the CEU (frequency 0.15) and YRI (0.02)
groups (Figure 4), but that it is a major allele in Asian
females (CHB: 0.56; JPT: 0.61). Like in the CHAVI sample,
no CC homozygotes were present among the CEU and
YRI females. In contrast, homozygous and heterozygous
female carriers of C were fairly frequent in CHB (CC:
0.35; CT: 0.43) and JPT (CC: 0.41; CT: 0.41). Similarly, C
hemizygous males were a rare (0.1) group in CEU, and
even rarer in YRI (0.03), but were fairly prevalent among
males of Asian origin (CHB: 0.36; JPT: 0.54). Thus, on the
basis of the hypothesis that the rs5968255 C allele exerts
the same effect upon the progression phenotype in Asians
as in Europeans (Figure 2), more HIV-1-infected females in
China and Japan than in Europe would be predicted to
show delayed CD4 cell decline.
Discussion
To our knowledge, we have undertaken the ﬁrst genome-
wide search for host factors that impact upon disease
progression in SIV-infected rhesus macaques, one of the
most important animal models of human AIDS. Our data
not only conﬁrmed the importance of theMHC class I locus
for this phenotype but also, to our knowledge, for the ﬁrst
time identiﬁed X chromosomal variation as being signiﬁ-
cantly associated with AIDS-free survival in primates. This
information then allowed us to identify a variant in the
orthologousXq21.1 region as being signiﬁcantly associated
with a disease-progression phenotype in HIV-infected
humans, an association that otherwise would have been
overlooked. Over and above their scientiﬁc relevance, our14, 2009
results deserve speciﬁc attention because they highlight
how cross-species analyses can successfully translate
genetic association ﬁndings from an animal model to
a human disease, even over an evolutionary distance of
25 million years.
In the screening stage (stage 1) of our rhesus GWAS, two
MHC class I markers were found to be signiﬁcantly associ-
ated with a score measuring differential progression to
AIDS-related disease, and these polymorphisms also
achieved nominal signiﬁcance in the veriﬁcation stage
(stage 2). Such a contribution by the MHC region was not
unexpected. Both markers map only 400 kb apart from
each other, and ﬂank the A region of the rhesus macaque
MHC class I. Marker D6S2704 is located 150 kb distal to
the ZNRD1 (zinc ribbon domain-containing protein 1
[MIM 607525]) and RNF39 (ring ﬁnger protein 39 [MIM
607524]) genes, and polymorphisms in these genes have
been reported before to inﬂuence HIV-1 disease progres-
sion in humans.1,2,4,5,28 ZNRD1 was also identiﬁed in
a recent search for HIV-1 dependency factors (HDFs) that
may be involved in the viral life cycle.6 Inspection of the
microsatellite genotypes of stage 1 revealed the presence
Figure 3. Characteristics of the Genomic
Region around X-Chromosomal SNP
rs5968255, Associated with the Progres-
sion Phenotype in Humans
(A) Ideogram of the human X chromo-
some. The position of rs5968255 at
Xq21.1 (NCBI Build 36.1: 83,141,348) is
indicated in red.
(B) Partial map of Xq21.1 (coordinates
82,887,000 to 83,471,000) depicting the
location of genes close to rs5968255
(marked by an arrow) and the local pattern
of LD in the HapMap CEU sample. This
graph was created with the WGAViewer.61
(C) Evolutionary conservationwithin a 1 kb
window centered on rs5968255 (coordi-
nates83,140,849 to83,141,848); theconser-
vation data were obtained from the UCSC
Genome Browser; Vertebrate Multiz Align-
ment62 and PhastCons Conservation.63
of only four alleles of D6S2972. Two
of them were perfectly associated
with rhesus MHC class I allele Mamu-
A*01, which may explain the associa-
tion between D6S2972 and the
progression score in stage 1.12,13,28,31
In stage 2, D6S2972 was found to be
less tightly associated with Mamu-
A*01, and this maybe why the pheno-
type association did not withstand
multiple testing correction (see
Figure S4). The association between
D6S2704 and the progression score
may also be explained in part by
linkage of D6S2704 to particular
MHC genes. However, because of the
close physical proximity between D6S2704 and ZNRD1,
the causal variation underlying the observed phenotype
association must remain elusive until a more detailed anal-
ysis of the nonclassical-MHC genes within this region has
been carried out.
Most importantly, an X chromosomal marker was found
to be signiﬁcantly associated with the progression score in
both stages of our rhesus GWAS. Given that no evidence
for an involvement of X chromosomal variation into the
course of HIV-1 infection has been reported before, we
aimed at replicating this ﬁnding in humans. In so doing,
we identiﬁed SNP rs5968255 as being associated with a
progression phenotype related to the rate of CD4 cell
decline in HIV-1-infected patients, independent of the
MHC. We found that the minor C allele of this variant is
beneﬁcial for heterozygous females, whereas the progres-
sion phenotype in women with the TT genotype was the
same as that of male patients. The fact that C hemizygous
males did not beneﬁt from the protective allele suggests
that its inﬂuence may depend upon the background of
female physiology or genetics.32,33 No CC homozygous
women could be analyzed because none were present inThe American Journal of Human Genetics 85, 228–239, August 14, 2009 235
the CHAVI sample. Therefore, it would be too premature to
speculate about a possible heterozygosity effect. Notably,
our initial study of rhesusmacaques revealed no signiﬁcant
sex difference in terms of the observed genotype-pheno-
type relationship (Figure S5), but this may have been due
to a lack of power because females were underrepresented
in both stages of the GWAS (Table 1). Such sex imbalance
is a common phenomenon in potentially lethal experi-
ments in primate research because primate centers have
to retain females for breeding. Another explanation for
the discrepant sex speciﬁcity in humans and monkeys
could be that different genes encoded in the same X chro-
mosomal region affect the disease differently. However, it
appears more plausible that identical X-linked mecha-
nisms inﬂuence AIDS symptom-free survival time in both
species, but that the overt phenotype is modiﬁed by
species-speciﬁc variants that arose during the 25 million
years of evolutionary divergence between humans and
macaques.
Intergenic SNP rs5968255 marks a >300 kb region that
must contain the causal variation underlying the sex-
speciﬁc phenotype association observed in our study.
Unfortunately, all SNPs in strong LD with rs5968255
were mainly intergenic or intronic and did not immedi-
ately suggest functional candidates for further investiga-
tion. Furthermore, a query of gene-expression databases
indicated that rs5968255 is unlikely to inﬂuence the
expression level of nearby genes (Figure 3). Therefore, the
question whether RPS6KA6 or CYLC1 are functionally
involved in the observed phenotype association remains
open. So far, neither of the two genes has been implicated
in HIV-1/SIV-induced disease. The RPS6KA6 gene encodes
a member of a family of four ribosomal serine/threonine
kinases (RSK1-4 [MIMs 601684, 300075, 601685, and
300303]), three of which have been studied in detail before
Figure 4. Allele Frequencies of SNP rs5968255 in HapMap
The pooled (female and male) allele frequencies differed signiﬁ-
cantly between all population groups (all Bonferroni corrected
p < 0.001), except for the two Asian samples (CHB versus JPT:
c2 ¼ 4.545, 1 d.f., corrected p ¼ 0.198, nominal p ¼ 0.033).236 The American Journal of Human Genetics 85, 228–239, August 1(RSK1-3) and which were found to be involved in MAPK-
(MIM 176872), ERK- (MIM 601795), and mTor-(MIM
601231) signaling important for cell proliferation and
survival.34 All four proteins potentially function as media-
tors of the growth-factor- and stress-induced activation
of transcription factors. Consequently, they have been
examined in detail mainly in cancer studies but, at least
indirectly, these proteins may also be involved in HIV-1
infection. For example, RSK2 can regulate cAMP regulatory
element binding protein (CREB [MIM 123810]), and CREB
can interact with HIV-1 protein Tat.35 RPS6KA6 may be
different from the other ribosomal kinases in that it seems
to be fully activated in unstimulated cells,36 and overex-
pression in human breast cancer cells results in suppressed
proliferative activity of these cells.37 Another indirect link
with HIV-induced disease may derive from the fact that
overexpression of RPS6KA6 results in upregulation of clau-
din 2 (MIM 300520) and downregulation of the chemo-
kine receptor CXCR4 (MIM 162643). CXCR4 is highly
expressed in human malignant breast tumors and is a
coreceptor of HIV-1. Furthermore, RPS6KA6 may be regu-
lated by c-Myc (MIM 190080), which is also involved
in HIV-1 expression.38 So far, it is not known whether
RPS6KA6 is involved in CXCR4 receptor expression in
lymphocytes, but it may be speculated that CXCR4 expres-
sion is related to progression to AIDS. HIV-1 transmission
usually occurs by infection with viruses utilizing the che-
mokine receptor CCR5 (MIM 601373) for entry. However,
after retroviral infection, HIV-1 variants arise that can use
CXCR4 as a coreceptor. Although, the underlying mecha-
nism is still enigmatic, this virus-coreceptor switch is
known to be associated with the rate of progression to
AIDS.39 On the other hand, even if RPS6KA6 were involved
in differential CXCR4 expression in lymphocytes, thereby
inﬂuencing viral coreceptor density on the cell surface,
it would be unclear why this should have an effect in
heterozygous women alone. It would also not explain
why the RPS6KA6 gene should affect disease progression
in SIV-infected monkeys because a coreceptor switch
does not occur in monkeys. Claudin 2 is a tight-junction
protein that is expressed, for example, in the intestine,
i.e., a tissue that is severely impaired by HIV infection.
Claudin proteins have been implicated in virus entry and
dissemination in various infections, including HIV infec-
tion of the brain.40–43 Notably, claudin 2 is also encoded
by an X chromosomal (Xq22.3) gene.
The second gene close to rs5968255 is CYLC1, proposed
to encode a basic protein of the sperm head cytoskeleton.
Yet, it appears to be expressed in other cell types such as
brain and kidney cells and may be expressed at low levels
in cells of lymphoid origin.44 Unfortunately, the function
ofCYLC1has not been investigated so far so that the poten-
tial role of this gene in HIV pathogenesis must remain
unclear.
Sex-speciﬁc genetic factors have been suspected for some
time to inﬂuence the course of AIDS in humans,32,45,46 but
these could never be established ﬁrmly by epidemiological4, 2009
studies. Although it seems clear that women are more
vulnerable to the acquisition of HIV-1 than men,47,48
reports on sex-speciﬁc differences in HIV-1-induced disease
and mortality have been controversially discussed most
probably because these studies differed in terms of statis-
tical power and prevalent socioeconomic factors, such as
accessibility to the health care systems. In addition, lower
viral RNA load may not always be associated with slower
progression to AIDS.49 This notwithstanding, several
studies suggested that women tend to progress to AIDS
more slowly than men. Such a phenomenon that became
even more prominent after the introduction of highly
active antiretroviral therapy.50–53 Other reports repeatedly
claimed that, after stratiﬁcation by CD4 cell count, HIV-
infected women have a lower viral load than HIV-infected
men54–56 and that CD4 cell counts tend to be higher and
associated with lower viral RNA levels in infected females
than males.32 The latter observation is consistent with
the view that the higher CD4:CD8 ratio in females is genet-
ically determined,57 although the underlying variation is
yet to be discovered. According to our results, only a genet-
ically deﬁned minority of women in Europe and Africa
may in fact beneﬁt from a prolonged nonsymptomatic
state after HIV-1 infection. This is not surprising because,
in Europe, AIDS became a medical problem only one
generation ago, and its prevalence is still far too low to
have induced sufﬁcient selective pressure in favor of the
C allele in the past. The reason why this allele is much
more frequent in Asians is unclear, but we do not presume
that it is in any way related to HIV-1 infection. Further-
more, it still remains to be investigated whether a higher
frequency of Asian HIV-1-infected females indeed experi-
ence a prolonged nonsymptomatic disease state.
Sex speciﬁcity clearly adds to the complexity of the role
of host factors in HIV-1 infection and, consequently,
impinges upon issues such as antiretroviral treatment
and vaccine efﬁcacy. Our understanding of how different
immune responses to pathogens arise in the two sexes,
and speciﬁcally how HIV-1 affects the sexes differently, is
still very limited.32,33 So far, such sex differences were
mainly attributed to different sex steroid hormone levels
or, for example, a generally higher CD4:CD8 ratio in
females.32,33,57 However, the process of X chromosome
inactivation (XI), and a potential skew of XI, also has to
be taken into account when trying to explain the sex-
speciﬁc manifestation of heritable traits.58 At least 15%
of X-linked genes can escape XI and the skew of XI
increases with age.59,60 Whether the observed association
between rs5968255 and progression phenotype entails
an interaction with XI remains to be elucidated.
To our knowledge, we have provided the ﬁrst ﬁrm
evidence for an association between X chromosomal
genetic variation and two of the best predictors of HIV-1
disease progression, namely CD4 cell decline and VL at
set point. Previous studies also suggested that several X
chromosomal host genes are necessary for the HIV-1 life
cycle.6 Therefore, considerablymore genetic variation thanThe Ameriuncovered by our study can still be expected to play a role in
the sex speciﬁcity of HIV-1 susceptibility and the progres-
sion to AIDS in humans.
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